Literature DB >> 26629267

Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2015        PMID： 26629267      PMCID： PMC4665066     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  12 in total

1.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

Review 2.  The global burden of hepatitis C.

Authors:  Daniel Lavanchy
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

Review 3.  Direct-acting antiviral agents for hepatitis C virus infection.

Authors:  Jennifer J Kiser; Charles Flexner
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-11-05       Impact factor: 13.820

4.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 5.  Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.

Authors:  F Poordad; D Dieterich
Journal:  J Viral Hepat       Date:  2012-07       Impact factor: 3.728

Review 6.  Chronic hepatitis C: an age wave of disease burden.

Authors:  John G McHutchison; Bruce R Bacon
Journal:  Am J Manag Care       Date:  2005-10       Impact factor: 2.229

7.  Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.

Authors:  Gary L Davis; Miriam J Alter; Hashem El-Serag; Thierry Poynard; Linda W Jennings
Journal:  Gastroenterology       Date:  2009-10-25       Impact factor: 22.682

8.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

Review 9.  Current prospects for interferon-free treatment of hepatitis C in 2012.

Authors:  Catherine A M Stedman
Journal:  J Gastroenterol Hepatol       Date:  2013-01       Impact factor: 4.029

10.  Current and future disease progression of the chronic HCV population in the United States.

Authors:  Martin Zalesak; Kevin Francis; Alex Gedeon; John Gillis; Kyle Hvidsten; Phyllis Kidder; Hong Li; Derek Martyn; Leslie Orne; Amanda Smith; Ann Kwong
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240
View more
  6 in total

1.  Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015.

Authors:  Monica L Kasting; Anna R Giuliano; Richard R Reich; Richard G Roetzheim; David R Nelson; Elizabeth Shenkman; Susan T Vadaparampil
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-27       Impact factor: 4.254

2.  An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function.

Authors:  Shyam Patel; Jennifer Andres; Kamran Qureshi
Journal:  Case Rep Med       Date:  2016-08-22

Review 3.  Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study.

Authors:  Mahmoud H Teaima; Adi Al-Nuseirat; Dalia Abouhussein; Osama A Badary; Mohamed A El-Nabarawi
Journal:  J Pharm Policy Pract       Date:  2021-12-16

Review 4.  Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C.

Authors:  Spilios Manolakopoulos; George Zacharakis; Miltiadis Zissis; Vassilis Giannakopoulos
Journal:  Ann Gastroenterol       Date:  2016-05-11

5.  Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia.

Authors:  Almoutaz Hashim; Fadia Almahdi; Emad Aldin Albaba; Ohoud Barkia; Reem Alkasam; Asmaa Almahmoud; Ahmed Nabil; Ayman Alsulaimani; Mahmoud Mosli
Journal:  J Epidemiol Glob Health       Date:  2020-06

6.  Comparing direct acting antivirals for hepatitis C using observational data - Why and how?

Authors:  Jim Young; Stanley Wong; Naveed Z Janjua; Marina B Klein
Journal:  Pharmacol Res Perspect       Date:  2020-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.